Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4/A - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13G - OmniAb, Inc. (0001846253) (Subject)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13G - OmniAb, Inc. (0001846253) (Subject)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

SC 13D - OmniAb, Inc. (0001846253) (Subject)

OmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of Omn

Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms

APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022 Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual redemptions and estimated expenses, OmniAb expects to have approximately $95 million of net cash upon the closing of the Business

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies. The dividend in OmniAb shares is expected to be distributed to Ligand shareholders on or about November 1, 2022, the expected closing date of the previously announced business combination (Business Combination) between OmniAb and Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA). Following the closing of the Business Combination, APAC

Extraordinary General Meeting of APAC Shareholders to Vote on Proposed Business Combination with OmniAb to be Held on October 24, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Avista Public Acquisition Corp. II (NASDAQ:AHPA) ("APAC") announced today the effectiveness of the Registration Statement on Form S-4 filed with the Securities and Exchange Commission (the "SEC") in connection with the previously announced business combination (the "Business Combination") between APAC and OmniAb, Inc. ("OmniAb"), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand"). APAC also announced that the extraordinary general meeting of its shareholders (the "Special Meeting") to approve th

First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists using OmniAb's OmniRat antibody discovery technology.

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

Transaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Ligand's shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ:LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand's antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will be led by Ligand's President, Matt Foehr, and will

EFFECT - OmniAb, Inc. (0001846253) (Filer)

EFFECT - OmniAb, Inc. (0001846253) (Filer)

POS AM - OmniAb, Inc. (0001846253) (Filer)

S-3 - OmniAb, Inc. (0001846253) (Filer)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

424B3 - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

424B3 - OmniAb, Inc. (0001846253) (Filer)

10-Q - OmniAb, Inc. (0001846253) (Filer)

Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) jumped 153.9% to close at $3.30 on Friday. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) surged 61.4% to close at $0.92 after jumping 15% on Thursday. Nuvalent, Inc. (NASDAQ:NUVL) shares gained 60.6% to close at $35.34 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Bull Horn Holdings Corp. (NASDAQ:BHSE) jumped 44.7% to close at $11.95. Fangdd Network Group Ltd. (NASDAQ:DUO) gained 36.6% to close at $1.94. Provident Acquisition Corp. (NASDAQ:PAQC) shares jumped 32.7% to close at $11.00. Perfect Corp. and Provident Ac

Gainers Quanergy Systems, Inc. (NASDAQ:QNGY) surged 179% to $3.6301. Nuvalent, Inc. (NASDAQ:NUVL) shares jumped 62% to $35.60 after the company reported preliminary Phase 1 clinical data from the ARROS-1 trial that support the best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) climbed 38% to $0.7860 after jumping 15% on Thursday. Sierra Metals Inc. (NYSE:SMTS) gained 32% to $0.2201. Sierra Metals' largest shareholder and Compañia Minera Kolpa announced Letter of Intent for Sierra Metals transaction and financing. Rail Vision Ltd. (NASDAQ:RVSN) jumped 31.6% to $0.7899. Agrify Corporation (NASDAQ:AGFY) surged 31% to $2.1

First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms o

APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022 Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual redemptions and estimated expenses, OmniAb expects to have approximately $95 million of net cash upon the closing of the Business C

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies. The dividend in OmniAb shares is expected to be distributed to Ligand shareholders on or about November 1, 2022, the expected closing date of the previously announced business combination (Business Combination) between OmniAb and Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA). Following the closing of the Business Combination, APAC w

Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma.  Teclistamab is a T-cell redirecting bispecific antibody targeting both B-cell maturation antigen and CD3 discovered by Janssen scientists using Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) OmniAb OmniRat antibody discovery technology. Ligand's previously announced spin-off of OmniAb and merger (Business Combination) with Avista Public Acquisition Corp. II (NASDAQ: AHPA), a publicly traded special purpose acquisition company. Under the terms of the licensing agreement, OmniAb is eligible to receive

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto Novartis AG (NYSE:NVS) said the U.S. Food and Drug Administration approved Pluvicto for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer that has spread to other parts of the body. These patients have already been treated with other anti-cancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). The stock was edging up 0.44% to $85.93 in premarket trading. Ligand To Spin Off Anti

Ligand Pharmaceuticals Inc (NASDAQ:LGND) signed a merger agreement with Avista Public Acquisition Corp II (NASDAQ:AHPA), providing for the spin-off of OmniAb Inc. APHA is Avista Capital Partners-backed special purpose acquisition company (SPAC), and OmniAb is Ligand's antibody discovery business.  Ligand's President, Matt Foehr, will lead the combined company that will trade on NASDAQ under the ticker 'OABI.' Avista Capital will invest up to $115 million in the combined company, and Ligand will contribute $15 million.  Related: Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company. The combined company will have an initial pre-money equity valuation of $850 million.  Im

Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ:LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand's antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will be led by Ligand's President, Matt Foehr, and will be renamed "OmniAb, Inc." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005896/en/ Upon the closing of the transaction, Avista Capital Partners